Medindia

X

/C O R R E C T I O N -- Cardiogenesis Corporation/

Wednesday, August 15, 2007 General News J E 4
Advertisement
In the news release, Cardiogenesis Reports Second Quarter 2007 Results,issued earlier today by Cardiogenesis Corporation (OTC: CGCP) over PRNewswire, we are advised by the company that the ninth paragraph, firstsentence, should read "Cardiogenesis reported operating income of $209,000 forthe first six months of 2007 as compared with operating income of $266,000 forthe same period in the prior year" rather than "Cardiogenesis reported asecond quarter 2007 operating income of $209,000 as compared with operatingincome of $266,000 in the prior year quarter" as originally issuedinadvertently.



------

Cardiogenesis Reports Second Quarter 2007 Results

IRVINE, Calif., Aug. 14 /PRNewswire-FirstCall/ -- CardiogenesisCorporation (OTC: CGCP), a leading developer of surgical products andaccessories used in angina-relieving procedures, today reported financialresults for its second quarter ended June 30, 2007.

Sales in the second quarter of 2007 totaled $2,436,000, a decrease ofapproximately 45% as compared with $4,392,000 of sales in the prior yearquarter. The lower revenue in the current year quarter is primarilyattributable to a $1,146,000, or 38%, decline in disposable handpiece revenue,and an $849,000, or 79%, decline in capital sales as compared with the prioryear quarter. During the second quarter of 2007 the company sold 1 laser and512 handpieces as compared to 5 lasers and 798 handpieces during the secondquarter of 2006.

Sales in the first six months of 2007 totaled $5,806,000, a decrease ofapproximately 37% from the $9,241,000 recorded in the first six months of2006. The year to date decrease as compared with the prior year period isprimarily attributable to a $1,991,000, or 32%, decline in disposablehandpiece revenue and a $1,502,000, or 61%, decline in capital sales. For thefirst half of 2007, the company sold 6 lasers and 1,168 handpieces as comparedto 11 lasers and 1,717 handpieces for the first half of 2006.

The company attributed the decrease in sales for both the second quarterand first half of 2007 primarily to turnover of its sales force. Approximatelytwo-thirds of the sales force joined the company within the last 5 monthswhich significantly impacted sales in both the second quarter and first halfof 2007. Cardiogenesis President Richard P. Lanigan said, "During the secondquarter we largely completed our sales force expansion effort, successfullyrecruiting, hiring and training several new sales professionals. At quarterend, we had 14 of the targeted 16 domestic territory manager positions filled.Our new sales professionals appear to be gaining traction in their respectiveterritories and we are encouraged by the fact that during July, a normallyslow time of year, we experienced the highest monthly handpiece volume sinceFebruary."

Gross margin was 78% of sales for the quarter ended June 30, 2007 ascompared with an 81% gross margin realized in the second quarter of 2006.Gross profit in absolute dollars decreased by $1,656,000 to $1,905,000 for thecurrent year quarter as compared with $3,561,000 for the 2006 second quarter.The decrease in gross margin resulted primarily from the replacement of keycomponents on lasers being used at two international heart centers, at nocharge to the customer, to facilitate the re-implementation of TMR programs atthose centers. In addition, the company wrote off inventory previouslylocated in Europe to support sales of PMC product. For the six months endedJune 30, 2007, gross profit decreased to 80% of net revenues as compared to81% of the net revenues for the six months ended June 30, 2006. Gross profitin absolute dollars decreased by $2,888,000 to $4,632,000 for the six monthsended June 30, 2007, as compared to $7,520,000 for the six months endedJune 30, 2006.

Research and development costs were $297,000 in the second quarter of 2007as compared wi
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Future Lies in Service for In Vitro Diagnostic Equ...
S
WiFiMed Holdings Co. Completes Acquisition of JMJ ...